Results for this period
Third quarter1 July 2025 to 31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Research and development expenses increased by ¥104 million year on year, while selling, general and administrative expenses increased by ¥12 million, resulting in a ¥117 million increase in operating expenses. The company proceeded with preparations for the European Phase 3 clinical trial of CBP501 and for the CBT005 preclinical trial.
The notes state that there are “no applicable matters.” However, under “Significant events or conditions that may raise substantial doubt about the going concern assumption,” the company states that conditions exist that may raise substantial doubt about the going concern assumption because it has no product sales and no alliance relationships.
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 July 2025 to 31 March 2026 |
| Operating profit | ¥-916 million |
| Ordinary income | ¥-873 million |
| Profit attributable to owners of the parent | ¥-873 million |
| Net income per share | △44.35 |
| Equity ratio | End of the current fiscal period 92.3 / End of previous period 95.4 |
| Total assets | ¥2,206 million |
| Net assets | ¥2,074 million |
| Cash and cash equivalents at end of period | ¥1,765,302 thousand |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | Segment Pharmaceuticals Business / Net Sales Not disclosed / Year on year against the same period last year Not disclosed |
| Disclosure regarding the going concern assumption | The notes state that there are “no applicable matters.” However, under “Significant events or conditions that may raise substantial doubt about the going concern assumption,” the company states that conditions exist that may raise substantial doubt about the going concern assumption because it has no product sales and no alliance relationships. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 19,713,655 |
| Treasury Shares at Period-End | 10,598 |
| Factors Behind Changes in Business Performance | Research and development expenses increased by ¥104 million year on year, while selling, general and administrative expenses increased by ¥12 million, resulting in a ¥117 million increase in operating expenses. The company proceeded with preparations for the European Phase 3 clinical trial of CBP501 and for the CBT005 preclinical trial. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Research and development expenses increased due to preparations for the European Phase 3 clinical trial of CBP501 and preparations for the CBT005 preclinical trial, while selling, general and administrative expenses also increased.